Martin Kolev
Director Complement Science Apellis Pharmaceuticals
I am a trained PhD immunologist with an extensive experience in the complement system and CD4+ T cell biology. I have multiyear scientific experience working in top academic institutions and pharma industry (GSK and Apellis) . Throughout my career I have also gained deep understanding and appreciation of different cultures and approaches to working having lived and worked in Denmark, Germany, UK and USA. Currently, my main scientific interests are in understanding how underlying defects in immunometabolism modulate T cell memory differentiation and their contribution to autoimmune diseases and cancer.
Seminars
Wednesday 22nd July 2026
Panel Discussion: Positioning Novel Mechanisms in the Myasthenia Gravis Market to Deliver Differentiated Patient Benefit
9:30 am
- Comparing how FcRn inhibition, complement blockade, B-cell depletion and CAR-T differ mechanistically and where each may sit best based on disease biology
- Examining how mechanistic sequencing could address patients exposed to prior lines of therapy without clear biomarkerguidance
- Identifying emerging strategies for treating MG patients who fail FcRn inhibition, IgG degraders or complement therapies
- Gain insight into how to position assets in a saturated market while addressing inadequate responders and future curative ambition
